Europe

Former Merck Serono headquarters in Geneva could host a new Wyss Institute

Friday, December 7, 2012 01:43 PM

A dedicated consortium comprised of the École Polytechnique Fédérale de Lausanne (EPFL), the University of Geneva (UNIGE), Dr. Hansjörg Wyss and the Bertarelli family has developed a project to convert part of the former Merck Serono site in Geneva, Switzerland, into a multi-development facility.

More... »

ACM Global relocates to expanded lab facilities in Europe

Friday, December 7, 2012 12:19 PM

The central laboratory of ACM Global, a clinical trials testing service, has been relocated its laboratory facilities in York, England.

More... »

Almirall’s Constella approved in Europe for IBS-C

Wednesday, November 28, 2012 12:20 PM

The European Commission has granted marketing authorization to Almirall’s Constella (linaclotide 290mcg) for the symptomatic treatment of moderate to severe Irritable Bowel Syndrome with Constipation (IBS-C) in adults . This approval follows the positive recommendation received from the European Committee for Medicinal Products for Human Use (CHMP) in September.

More... »

EFPIA gives recommendations for clinical trial data transparency

Tuesday, November 27, 2012 02:43 PM

The European Federation of Pharmaceutical Industries and Associations recently held a workshop to give insight into the different views on the sensitive issue of clinical data transparency in Europe.

More... »

Qualcomm Life launches wireless health solution in Europe

Tuesday, November 13, 2012 01:03 PM

Qualcomm Life, a subsidiary of Qualcomm Technologies (QTI), has launched its wireless healthcare services offering in Europe.

More... »

CEO of Sanofi designated as new president elect of EFPIA

Wednesday, November 7, 2012 01:55 PM

The European Federation of Pharmaceutical Industries and Associations (EFPIA), which represents the pharmaceutical industry operating in Europe, has designated Christopher A. Viehbacher, CEO of Sanofi, as the new president elect of EFPIA. He will take up the position as of June 2013 for a two year term.

More... »

U.K. government awards $2.7M grant to PsiOxus cancer vaccine

Wednesday, November 7, 2012 10:57 AM

PsiOxus Therapeutics, a development stage biotechnology company based in the U.K was awarded a $2.7 million grant from the U.K. government-backed Biomedical Catalyst to initiate a phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent ovarian cancer.

More... »

Curie-Cancer, Harmonic to explore anti-cancer activity of several compounds

Monday, November 5, 2012 03:21 PM

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and Harmonic Pharma, a French company focused on extending the therapeutic application of compounds already on the market, have entered into a research collaboration aimed at exploring the anti-cancer activity of several molecules in Harmonic’s portfolio.

More... »

More than $1.6B to be invested in U.K. science and research

Friday, November 2, 2012 02:48 PM

Seven new university and business research projects won bids from the U.K. Research Partnership Investment Fund (UK RPIF), doubling the number of winning bids to 14. When complete, the scheme will deliver more than $1.6 billion of new funding for research from government, industry and charities.

More... »

Menarini, Oxford BioTherapeutics to collaborate on portfolio of antibody-based cancer drugs

Tuesday, October 30, 2012 11:52 AM

Menarini Group, an international pharmaceutical company based in Italy, and Oxford BioTherapeutics (OBT), an international biotechnology company based in the U.K., have formed a major innovative and strategic alliance to develop a portfolio of antibody-based drugs in the field of cancer.

More... »